ClinicalTrials.gg
RecruitingNCT03827876Updated Feb 4, 2019

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

A Phase 4 interventional study of Enstilar 0.005%-0.064% Topical Foam in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-04.

Sponsored by Psoriasis Treatment Center of Central New Jersey · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2019, 7 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jan 2019; still recruiting 7 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey — 5 open to participants now, 5 under way, none of them phase 3. Psoriasis · Psoriasis Treatment Center of Central New Jersey.

Planned enrollment
2nd of 12
30 · median 27
Started
2019
with 2 others
Phase 4
11 of 13
4 open now
Registered
7th of 13
by date

Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2019, is one of 11 in phase 4, and was the 7th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, or all of them as a file.
02

Study summary

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Read the detailed description

30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult ≥ 18 years of age;
  • Diagnosis of chronic plaque-type
  • Patient with 2-10% BSA
  • Physician Global Assessment of 2 or greater
  • Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion criteria

Exclusion Criteria:

  • ˂2 or >10% BSA
  • PGA \<2
  • Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Open Label Enstilar

    once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira

    Drug: Enstilar 0.005%-0.064% Topical Foam

Interventions

  • DrugEnstilar 0.005%-0.064% Topical Foam

    Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira

06

What researchers measure

Primary outcomes

  1. PGA x BSA improvement

    body surface area multiplied by physician global assessment

    Time frame: 16 weeks

Secondary outcomes

  1. BSA improvement

    body surface area improvement

    Time frame: 16 weeks

  2. Dermatology Life Quality Index improvement

    patient reported outcome improvements of DLQI (Dermatology Life Quality Index). Calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30.

    Time frame: 16 weeks

  3. Itch Numerical Rating Scale

    Patient reported itch scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
    Recruiting
    • Elise Nelson · Contactenelson@windsordermatology.com · 609-443-4500
    • Jerry Bagel, MD · Principal investigator
    • Brian Keegan, MD, PhD · Sub investigator
    • David Nieves, MD · Sub investigator
    • Alexa Hetzel, PA-C · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Sep 2019, 7 months after the start.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 7 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Feb 4, 2019
StartActual
Jan 16, 2019
Primary completionEst.
Sep 15, 2019
CompletionEst.
Dec 15, 2019
Last update
Feb 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03827876
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Collaborators
LEO Pharma
Responsible party
Sponsor
First posted
Feb 4, 2019
Start date
Jan 16, 2019
Primary completion
Sep 15, 2019 (estimated)
Completion
Dec 15, 2019 (estimated)
Last update
Feb 4, 2019

Study contacts

Jerry Bagel, MD
Contact
dreamacres1@aol.com
6094434500
Elise Nelson
Contact
enelson@windsordermatology.com
6094434500

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion